With phage therapy, researchers sharpen another arrow in the quiver against anti...
In the wake of the state court ruling on frozen embryos, the U. of Alabama, Birm...
People with autoimmune disorders don’t usually get to talk about a cure. But a s...
Scientists have laid out a blueprint for creating a “universal antivenom.”
AbbVie announced that CEO Richard Gonzalez, who has managed its ascent since bei...
Why GLP-1 treatments like Wegovy could actually help dialysis companies, despite...
DarioHealth, with apps for managing chronic diseases, will acquire mental health...
A NIH study of myalgic encephalomyelitis, or chronic fatigue syndrome, points to...
In utero gene editing envisions treating a fetus diagnosed with a genetic diseas...
Medicare funding should be distributed based on need, not unequal territorial st...
Tippi MacKenzie envisions doing surgery without scalpels or sutures, editing fet...
RioDerm-001 is under clinical development by Rion and currently in Phase II for ...
SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and cur...
Not Disclosed Neurodegeneration is under clinical development by Eli Lilly and C...
RioDerm-004 is under clinical development by Rion and currently in Phase I for F...
Ketamine is under clinical development by NRX Pharmaceuticals and currently in P...
